There’s a balance required to manage both the symptoms of myelofibrosis through treatment and the side effects caused by the drugs, explained Firas El Chaer, MD, of the University of Virginia School of Medicine.
The significant symptom burden of myelofibrosis requires treatment to control symptoms, but the Janus kinase (JAK) inhibitors being used today can cause significant side effects that are hard to manage through dose adjustment or reduction and may require patients to switch to a different class of drug to maintain disease control of myeloproliferative neoplasms (MPNs), explained Firas El Chaer, MD, associate professor of medicine, University of Virginia School of Medicine.
This transcript has been lightly edited for clarity.
Transcript
What impact do the symptoms of MPNs have on the quality of life of patients?
Unfortunately, untreated myelofibrosis can be associated with significant symptom burden, and without treatment, those symptoms don't usually improve on their own. We're very lucky that we have drugs right now that can control those symptoms. However, unfortunately, in a lot of instances, the disease can relapse with these symptoms, progressing on further therapy, requiring additional therapeutic agents in the future. Those symptoms can be quite debilitating, so controlling them is very important.
What are common adverse events from MPN treatment and how can they best be managed?
Many of the JAK inhibitors that we use nowadays can have significant side effects, such as severe thrombocytopenia, severe anemia, and sometimes they can have GI [gastrointestinal] side effects. One drug, momelotinib, for instance, can have neuropathy side effects. And in some instances, these side effects can be very hard to manage. They might require dose reduction and drugs, which ultimately can lead to a subtherapeutic effect of those drugs. So, knowing how to dose adjust these medications to prevent further side effects is very important.
However, unfortunately, in a lot of instances, we cannot really dose reduce or dose adjust while keeping control of the disease, forcing us to switch to a different drug or different class of drugs to be able to treat those patients.
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Addressing Cancer Care Barriers Through Community Outreach and Support
February 4th 2025February 4 is World Cancer Day, and in these interviews with our Strategic Alliance Partner, NYU Langone Health, we learn about the importance of forming strong relationships with the communities you are located in and with whom you work to optimize cancer-related outcomes.
Read More
Olaparib Leads PARP Inhibitors in Boosting OS for Platinum-Sensitive Recurrent Ovarian Cancer
February 3rd 2025While all poly ADP-ribose polymerase (PARP) inhibitors improved progression-free survival, olaparib significantly extended overall survival (OS), making it a preferred option.
Read More
OIG Report Seeks Better Oversight, Records for FDA’s Accelerated Approvals
February 3rd 2025Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has been overlooked. It shows the need for reforms of the FDA's accelerated approval process.
Read More